

## References

- Agodoa, L.Y., Appel, L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. *JAMA* 1996; 285:2719-2727.
- Brenner, B.M., Cooper, M.E., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *The New England Journal of Medicine* 2001; 345:861-869.
- Cordonnier, D.J., Pinel, N., et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. *Journal of the American Society of Nephrology* 1999; 10:1253-1263.
- The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. *The Lancet* 1997; 349:1787-1792.
- The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *The Lancet* 1997; 349:1857-1863.
- Ihle, B.U., Whitworth, J.A., et al. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial. *American Journal of Kidney Diseases* 1996; 27:489-495.
- Laffel, L., McGill, J., Gans, D.J. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. *The American Journal of Medicine* 1995; 99:497-504.
- Lebovitz, H.E., Wiegmann, T.B., et al. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. *Kidney International* 1994; 45:S-150-S-155.
- Lewis, E.J., Hunsicker, L.G., Bain, R.P., Rohde, R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *The New England Journal of Medicine* 1993;329:1456-1497.
- Lewis, E.J., Hunsicker, L.G., et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *The New England Journal of Medicine* 2001; 345:851-860.
- Maschio, G., Alberti, D., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. *The New England Journal of Medicine* 1996; 334:939-945.
- Parving, H., Lehnert, H., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *The New England Journal of Medicine* 2001; 345:870-878.
- Ravid, M., Lang, R., Rachmani, R, Lishner, M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. *Arch Intern Med* 1996; 156:286-289.

Ruggenenti, P., Perna, A., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. *The Lancet* 1998; 352:1252-1256.

Ruggenenti, P., Perna, A., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. *The Lancet* 1999; 354:359-364.